journal article·2023-07Open access

Transformable Neuropeptide Prodrug with Tumor Microenvironment Responsiveness for Tumor Growth and Metastasis Inhibition of Triple‐Negative Breast Cancer

Yi Cao, Xiaojiao Ge, Xueli Zhu, Yingying Han, Pin Wang, Ozioma Udochukwu Akakuru, Aiguo Wu, Juan Li

Advanced Science· Volume 10· Issue 21

Abstract

Abstract Triple‐negative breast cancer (TNBC) has the worst prognosis among all breast cancer subtypes due to lack of specific target sites and effective treatments. Herein, a transformable prodrug (DOX‐P18) based on neuropeptide Y analogue with tumor microenvironment responsiveness is developed for TNBC treatment. The prodrug DOX‐P18 can achieve reversible morphological transformation between monomers and nanoparticles through the manipulation of protonation degree in different environments. It can self‐assemble into nanoparticles to enhance the circulation stability and drug delivery efficiency in the physiological environment while transforming from nanoparticles to monomers and being endocytosed into the breast cancer cells in the acidic tumor microenvironment. Further, the DOX‐P18 can precisely be enriched in the mitochondria, and efficiently activated by matrix metalloproteinases. Then, the cytotoxic fragment (DOX‐P3) can subsequently be diffused into the nucleus, generating a sustained cell toxicity effect. In the meanwhile, the hydrolysate residue P15 can assemble into nanofibers to construct nest‐like barriers for the metastasis inhibition of cancer cells. After intravenous injection, the transformable prodrug DOX‐P18 demonstrated superior tumor growth and metastasis suppression with much better biocompatibility and improved biodistribution compared to free DOX. As a novel tumor microenvironment‐responsive transformable prodrug with diversified biological functions, DOX‐P18 shows great potential in smart chemotherapeutics discovery for TBNC.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Neuropeptides and Animal Physiology · Nanoplatforms for cancer theranostics · Cancer, Stress, Anesthesia, and Immune Response

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Cixi Institute of Biomedical Engineering International Cooperation Base of Biomedical Materials Technology and Application CAS Key Laboratory of Magnetic Materials and Devices Zhejiang Engineering Research Center for Biomedical Materials Ningbo Institute of Materials Technology and Engineering Chinese Academy of Sciences 315201 Ningbo P. R. China

University of Chinese Academy of Sciences 100049 Beijing P. R. China

Funding

National Natural Science Foundation of China

References (52)

Show source-provided references
1. 10.1056/NEJMra100138910.1056/NEJMra1001389 ↗
2. 10.3322/caac.2170810.3322/caac.21708 ↗
3. 10.1016/S1470-2045(17)30904-X10.1016/S1470-2045(17)30904-X ↗
4. 10.1093/annonc/mdp49210.1093/annonc/mdp492 ↗
5. 10.1038/nrclinonc.2016.6610.1038/nrclinonc.2016.66 ↗
6. 10.1172/JCI4501410.1172/JCI45014 ↗
7. 10.1007/s10549-018-4697-y10.1007/s10549-018-4697-y ↗
8. 10.1158/2159-8290.CD-18-117710.1158/2159-8290.CD-18-1177 ↗
9. 10.1038/s41591-019-0432-410.1038/s41591-019-0432-4 ↗
10. 10.1016/S0140-6736(16)32454-010.1016/S0140-6736(16)32454-0 ↗
11. 10.1038/nature1650810.1038/nature16508 ↗
12. 10.1016/S1470-2045(07)70074-810.1016/S1470-2045(07)70074-8 ↗
13. 10.1016/j.cell.2018.03.04110.1016/j.cell.2018.03.041 ↗
14. 10.1016/j.addr.2017.06.01310.1016/j.addr.2017.06.013 ↗
15. 10.1021/jacs.8b0491210.1021/jacs.8b04912 ↗
16. 10.1002/anie.20211689310.1002/anie.202116893 ↗
17. 10.1021/acs.jmedchem.0c0138710.1021/acs.jmedchem.0c01387 ↗
18. 10.1021/acs.jmedchem.0c0153010.1021/acs.jmedchem.0c01530 ↗
19. 10.1039/D0CS00556H10.1039/D0CS00556H ↗
20. 10.1039/C7CS00521K10.1039/C7CS00521K ↗
21. 10.1021/acs.nanolett.8b0107110.1021/acs.nanolett.8b01071 ↗
22. 10.1038/s41467-019-12848-510.1038/s41467-019-12848-5 ↗
23. 10.1021/jacs.8b1351210.1021/jacs.8b13512 ↗
24. 10.1016/j.biomaterials.2021.12113910.1016/j.biomaterials.2021.121139 ↗
25. 10.1038/s41565-020-00782-310.1038/s41565-020-00782-3 ↗
26. 10.1038/s41565-019-0626-410.1038/s41565-019-0626-4 ↗
27. 10.1038/3500753410.1038/35007534 ↗
28. 10.1126/science.115866810.1126/science.1158668 ↗
29. 10.1016/j.neuron.2022.01.01010.1016/j.neuron.2022.01.010 ↗
30. 10.1210/er.2002-000710.1210/er.2002-0007 ↗
31. Reubi J. C. · J. Nucl. Med. · 2005 · 46 · 67S
32. 10.1016/j.eururo.2004.09.00710.1016/j.eururo.2004.09.007 ↗
33. Morgat C. · J. Clin. Invest. · 2014 · 55 · 1650
34. 10.1038/labinvest.370000910.1038/labinvest.3700009 ↗
35. 10.1158/0008-5472.CAN-05-274410.1158/0008-5472.CAN-05-2744 ↗
36. 10.1016/j.pharmthera.2011.03.01110.1016/j.pharmthera.2011.03.011 ↗
37. Reubi J. C. · Cancer Res. · 2001 · 61 · 4636
38. 10.1002/anie.20090500810.1002/anie.200905008 ↗
39. 10.1093/rb/rbv01310.1093/rb/rbv013 ↗
40. 10.1021/acsami.5b0027010.1021/acsami.5b00270 ↗
41. 10.1016/j.biomaterials.2016.11.02810.1016/j.biomaterials.2016.11.028 ↗
42. 10.1016/j.biomaterials.2018.04.00210.1016/j.biomaterials.2018.04.002 ↗
43. 10.1039/C8NR00148K10.1039/C8NR00148K ↗
44. 10.1039/C8NR02387E10.1039/C8NR02387E ↗
45. 10.1016/j.biomaterials.2019.01.00110.1016/j.biomaterials.2019.01.001 ↗
46. 10.1039/C9BM00337A10.1039/C9BM00337A ↗
47. 10.1007/s40820-019-0292-y10.1007/s40820-019-0292-y ↗
48. 10.1016/j.biomaterials.2014.02.00610.1016/j.biomaterials.2014.02.006 ↗
49. 10.1002/adma.20210816710.1002/adma.202108167 ↗
50. 10.1002/(SICI)1097-0215(19990219)84:1<44::AID-IJC9>3.0.CO;2-P10.1002/(SICI)1097-0215(19990219)84:1<44::AID-IJC9>3.0.CO;2-P ↗
51. 10.1002/(SICI)1097-0215(20000315)85:6<801::AID-IJC11>3.0.CO;2-C10.1002/(SICI)1097-0215(20000315)85:6<801::AID-IJC11>3.0.CO;2-C ↗
52. 10.1016/j.clinbiochem.2011.04.01910.1016/j.clinbiochem.2011.04.019 ↗